About ModernaCopy link to section
What is Moderna?Copy link to section
It’s a biotechnology company that develops therapeutics and vaccines using messenger RNA (mRNA) technology. Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna’s mRNA technology instructs cells in the body to trigger an immune response against certain diseases.
Moderna has several mRNA-based vaccines in the development stage but is best known for its Covid-19 vaccine, one of the first in the world to be approved.
How does Moderna make money?Copy link to section
It makes money by selling its products, including its mRNA-based vaccines and therapeutics. Moderna has secured government contracts and partnerships with other pharmaceutical companies helping it grow revenue to record levels in recent years.
While it is best known for its Covid vaccine, Moderna is also developing mRNA-based vaccines for various diseases, including the Zika virus, cytomegalovirus, and cancers.
What is Moderna’s best selling product?Copy link to section
By far, its best-selling product is its Covid 19 vaccine. Moderna made $18.4 billion in Covid 19 vaccine sales in 2022, with $10 billion of that amount coming from its deal with the U.S. government. The widespread use of its vaccine has contributed to the company’s growth and has allowed it to explore therapeutics for other diseases.
Who are the key executives at Moderna?Copy link to section
Its co-founder, Noubar B. Afeyan, is currently its Chairman. Here is a list of other key executives at Moderna.
- Noubar B. Afeyan Ph.D. Co-Founder, Independent Non-Exec. Chairman & Member of Technology Advisory Board
- Stephane Bancel. CEO & Director
- Stephen Hoge M.D. President
- Shannon Thyme Klinger. Chief Legal Officer & Corp. Sec. 1
- Juan Andres. Pres of Strategic Partnerships & Enterprise Expansion
- James M. Mock. Chief Financial Officer
- Jerh Collins Ph.D. Chief Technical Operations & Quality Officer
- Melissa J. Moore Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board
- Brad Miller. Chief Information Officer
- Lavina Talukdar CFA. Sr. VP & Head of Investor Relations
Where can I buy shares in Moderna?Copy link to section
You can buy Moderna stock on a stock trading platform. These platforms are extremely simple to use but there are different options to suit your specific needs. If you are a first-time investor you might want to use a trading platform for beginners, while if you plan on doing a lot of trading from your phone, a stock trading app might be best.
Are there any other ways to invest in Moderna?Copy link to section
The simplest way to invest in Moderna is to buy shares through a stock broker. However, you can also invest through an ETF or a fund. The best ETFs allow you to invest in the stock market more generally rather than focus on one company.
More about the MRNA priceCopy link to section
What is the Moderna stock price today?Copy link to section
The MRNA stock price today is currently $139.26, as of 27 February, 2023. The price of Moderna is down 8.9% over the past 52 weeks. You can use the live Moderna stock chart to track the NASDAQ:MRNA price in real time above, or compare the Moderna value today to its past performance using the Moderna financials tab at the top of this page.
What is the 52-week low for Moderna stock?Copy link to section
The 52-week low for Moderna stock is $115.03. MRNA stock is currently 20.85% above the 52-week low.
What is the 52-week high for Moderna stock?Copy link to section
The 52-week high for Moderna stock is $217.25. MRNA stock is currently 35.88% below the 52-week high.
What is the stock forecast for Moderna?Copy link to section
The average Moderna stock forecast has a price target of $231.36 by the end of 2023. Moderna’s latest financial results, the broader economic outlook, and the industry’s competition all influence these forecasts.
It’s best to take analyst forecasts with a grain of salt but you can use their estimates to help you understand the weight of opinion about a stock.
More stock guidesCopy link to section
FAQsCopy link to section
Latest Moderna newsCopy link to section
Recent Moderna analysisCopy link to section
Invezz is a place where people can find reliable, unbiased information about finance, trading, and investing – but we do not offer financial advice and users should always carry out their own research. The assets covered on this website, including stocks, cryptocurrencies, and commodities can be highly volatile and new investors often lose money. Success in the financial markets is not guaranteed, and users should never invest more than they can afford to lose. You should consider your own personal circumstances and take the time to explore all your options before making any investment. Read our risk disclaimer >